Related by context. All words. (Click for frequent words.) 70 GSTP1 69 T#I [002] 69 advanced adenomas 69 EGFR mutations 69 HER2 overexpression 69 basal cell nevus syndrome 69 epithelial tumors 68 KRAS mutations 68 BRAF mutation 68 K ras mutations 68 WT1 68 renal cell carcinomas 67 KRAS oncogene 67 gastrointestinal stromal tumors GISTs 67 Clusterin 67 HGPIN 67 B7 H3 67 ERBB2 67 carcinoembryonic antigen 67 pCR 67 CIN2 + 67 Her2/neu 66 TTR gene 66 node metastases 66 hypermethylated 66 GISTs 66 HAAH 66 Gleevec resistant 66 imatinib Gleevec 66 GNAQ 66 clusterin 66 MGd 66 EGFR mutation 65 basal cell carcinoma BCC 65 serous ovarian cancer 65 MGUS 65 colorectal neoplasms 65 GSTM1 65 lymph node metastases 65 mutated K ras 65 nanomolar 65 hepatocellular carcinomas 65 KIT mutations 65 relapsed MM 65 PKCi 65 histological subtype 65 EGFR tyrosine kinase inhibitors 65 nonmelanoma skin cancers 65 LRP5 65 chromosomal aberrations 65 Stat5 65 BRAF gene 65 colorectal carcinoma 65 somatic mutations 65 BRAF V#E mutation 65 IGF IR 64 breast carcinomas 64 HER2 expression 64 MALT lymphoma 64 BCR ABL mutations 64 HER2 receptor 64 trastuzumab Herceptin ® 64 trans retinoic acid 64 differentiated thyroid 64 squamous cell lung cancer 64 NRTI resistance 64 BRAF V#E 64 Squamous 64 invasive carcinomas 64 thyroglobulin 64 GSTT1 64 recurrent glioblastoma multiforme 64 histologic subtype 64 proto oncogene 64 hematopoietic cancers 64 KRAS mutation 64 benign moles 64 prostate cancer CaP 64 advanced adenoma 64 colorectal adenoma 64 BRCA2 mutation carriers 64 EGFR receptor 64 MLH1 64 mucinous 64 TNF blocker therapy 64 C#Y 64 K#N 64 invasive ductal 64 imatinib resistant 64 colorectal carcinomas 64 IGFBP 3 63 MSH2 63 p# mutation 63 ERCC1 63 HER2/neu 63 seminoma 63 dasatinib 63 cisplatin resistant 63 gastric adenocarcinoma 63 sarcosine 63 leukemia AML 63 distant metastasis 63 precursor lesions 63 MAGE A3 63 lymph node metastasis 63 EGF receptors 63 Adenomas 63 advanced neoplasia 63 urothelial carcinoma 63 chromosomal rearrangement 63 EpCAM expression 63 HBeAg 63 HER2 amplification 63 neoplasias 63 liver metastasis 63 cardiac troponin T 63 hormone receptor negative 63 K#R [002] 63 NF kB pathway 63 N. gonorrhoeae 63 RAS mutations 63 myelofibrosis polycythemia vera 63 pulmonary metastases 63 EphA2 63 pancreatic adenocarcinoma 63 malignant lesions 63 colorectal polyp 63 thrombin receptor 63 LRP6 63 isoproterenol 63 adenocarcinomas 63 familial pancreatic cancer 63 sCJD 63 SPINK1 63 grade gliomas 63 NNRTI resistance 63 antibody titer 63 KRAS wild 63 activating mutations 63 PTPN# 63 intestinal metaplasia 63 transgene expression 63 NMIBC 63 Folfox 63 mesothelin 63 thalidomide Thalomid 63 specific antigen PSA 63 immunoglobulin G 63 neuroblastoma tumors 63 TRAIL R2 63 premalignant lesions 63 grade cervical intraepithelial 63 FLT3 63 EGF receptor 62 E selectin 62 Immunohistochemical analysis 62 cytokeratin 62 Papillary 62 eosinophil count 62 PCa 62 anaplastic lymphoma kinase ALK 62 clinically detectable 62 IL#B 62 troponin T 62 atypical hyperplasia 62 HbF 62 PARP inhibition 62 Doxil ® 62 CLL cells 62 endoglin 62 KRAS status 62 tumorigenicity 62 erlotinib Tarceva 62 paricalcitol 62 metastatic gastric 62 erlotinib Tarceva ® 62 TNF α 62 HNSCC 62 metastatic lesions 62 EGFR TKI 62 endometrial hyperplasia 62 BRCA deficient 62 cisplatin chemotherapy 62 atypical hemolytic uremic syndrome 62 EGFR mutant 62 leukemias lymphomas 62 EpCAM 62 malignant lymphoma 62 medullary thyroid cancer 62 COX2 62 CYT# potent vascular disrupting 62 Hurthle cell 62 PIK3CA 62 TMPRSS2 ERG 62 cell adhesion molecule 62 cervical intraepithelial neoplasia 62 Upregulation 62 contralateral breast 62 thyroid carcinoma 62 CDDO Im 62 Epidermal Growth Factor Receptor 62 HepG2 cells 62 IFN beta 62 invasive lobular 62 alkaline phosphatase ALP 62 chemosensitivity 62 lactate dehydrogenase LDH 62 deletion 5q 62 CDH1 62 sarcomatoid 62 lung metastasis 62 Platinol ® cisplatin 62 Endometrial 62 breast carcinoma 62 Leukemias 62 imatinib therapy 62 adriamycin 62 BCL#A 62 alkylating agent 62 TGFBR1 * 6A 62 PDGF receptor 62 taxane therapy 62 AGTR1 62 GPNMB 62 #F FDG 62 interferon IFN 62 rs# [002] 62 Zolinza 62 hypermethylation 62 Aurora kinase 62 cyclin E 62 gemcitabine carboplatin 62 E. faecalis 62 metastatic colorectal 62 dexamethasone Decadron 62 FGFR2 62 basal cell carcinomas 62 pDCs 62 hamartomas 62 CIN3 + 62 Paraplatin ® carboplatin 62 NKG2D 62 RRM1 62 gene amplification 62 neoplastic 62 HER2 neu 62 chemo immunotherapy 62 gefitinib Iressa 62 Vidaza ® 62 mesotheliomas 62 lymphoid malignancies 62 PSA nadir 62 TT genotype 62 ADPKD 62 KIF6 gene 62 CC genotype 61 ABCB1 61 metastatic pancreatic 61 DFMO 61 mutated KRAS 61 EGFR inhibitors 61 H pylori 61 μg ml 61 microsatellite instability 61 c MYC 61 Xelox 61 MAP kinase 61 cutaneous melanoma 61 μmol L 61 V#F mutation 61 VEGFR1 61 nephrotoxicity 61 adenomatous 61 APOE e4 61 chemoresistance 61 ductal lobular 61 selective modulator 61 follicular lymphoma 61 caspofungin 61 metastatic bladder 61 TIMP 1 61 heterozygotes 61 pheochromocytomas 61 CYP#B# 61 VEGF inhibitors 61 PDGFR 61 Ki# 61 bronchogenic carcinoma 61 ertapenem 61 metastatic malignant 61 EGFR protein 61 HLA DRB1 * 61 Nilotinib 61 STAT1 61 untreated metastatic melanoma 61 receptor tyrosine kinase inhibitor 61 HBeAg negative 61 p# antigen 61 nonmetastatic 61 papillary renal cell carcinoma 61 lymphovascular invasion 61 autoantibody positive 61 colorectal tumors 61 bladder cancers 61 sorafenib Nexavar 61 efaproxiral 61 heparanase 61 adenoma 61 vimentin 61 autoantibodies 61 acid phosphatase PAP 61 ETV1 61 prostate carcinoma 61 BCR ABL 61 dacarbazine DTIC 61 anthracycline taxane 61 Li Fraumeni 61 PNET 61 CDK4 61 neuroendocrine cancers 61 KRAS gene 61 effector function 61 mTOR inhibitors 61 cTnI 61 metaplasia 61 virulence genes 61 adenomatous polyps 61 tumors GIST 61 p# mutations 61 liposomal doxorubicin 61 leukemia CLL 61 situ LCIS 61 HSCT 61 CCR7 61 mutant KRAS 61 HER2 gene 61 micrometastases 61 colorectal neoplasia 61 monocytic 61 XL# inhibits 61 pancreatic prostate 61 hepatoma 61 colon tumors 61 refractory NSCLC 61 unresectable tumors 61 alanine aminotransferase ALT 61 CIMZIA ™ 61 hypereosinophilic syndrome 61 squamous 61 postoperative chemotherapy 61 prostate cancer PCa 61 intestinal polyps 61 alkylating agents 61 familial ALS 61 TNFa 61 cervical lesions 61 elevated LDH 61 immunohistochemical 61 CIN3 61 follicular lymphoma FL 61 BMPR2 61 nonsmall cell lung cancer 61 multidrug resistance 61 SERMs 61 histopathologic examination 61 orally administered inhibitor 61 M. pneumoniae 61 demonstrated antitumor activity 61 Tumor Necrosis Factor 61 hCG Beta 61 idarubicin 61 nucleoside analogues 61 xenograft tumors 61 T1c 61 PC# cells 61 receptor tyrosine kinase 61 germline mutations 61 p# activation 61 HIV HCV coinfected 61 HER-2/neu 61 androgen receptor AR 61 GBM tumors 61 metastatic melanomas 61 picomolar 61 osteopontin 61 liver metastases 61 hyperplastic 61 lymphocytosis 61 hTERT 61 VEGF receptor 61 cranial irradiation 61 malignant nodules 61 prognostic significance 61 tumoral 61 Velcade bortezomib 61 locoregional recurrence 61 MTHFR 61 Bcr Abl mutations 61 nodal metastasis 61 bleomycin 61 mCRC patients 60 colorectal gastric 60 oblimersen 60 trophoblast cells 60 PI3K AKT 60 MYCN amplification 60 Estrogen Receptor 60 miR #a [002] 60 missense mutations 60 IgG antibody 60 Immunohistochemical staining 60 K ras 60 solar keratosis 60 flavopiridol 60 FGFR1 60 metastatic GIST 60 pancreatic lung 60 tyrosine kinase inhibitors 60 prostate adenocarcinoma 60 peritoneal carcinomatosis 60 gastric carcinoma 60 Foxp3 60 BRCA1 mutations 60 p#INK#a 60 RAS pathway 60 elevated CRP 60 pan HDAC inhibitor 60 achieved CCyR 60 alkaline phosphatase 60 tuberculin skin testing 60 Soft Tissue Sarcoma 60 EGFr 60 Basal Cell 60 CIN2 60 TOP2A 60 lobular carcinoma 60 ERK signaling 60 chronic eosinophilic leukemia 60 adrenocortical 60 pegylated liposomal doxorubicin 60 hypercalcemia 60 haematologic 60 RET PTC rearrangements 60 immunoreactivity 60 PUVA 60 seropositivity 60 B CLL 60 uveal melanoma 60 hA# 60 basal cell cancers 60 EGFRvIII 60 allogeneic HSCT 60 ApoE4 60 CLL SLL 60 thyrotropin levels 60 cervical neoplasia 60 Adjuvant chemotherapy 60 OGG1 60 baseline LDH 60 IFN γ 60 F FDG PET 60 basal cell skin 60 homozygotes 60 Haptoglobin 60 ERK1 2 60 Anaplastic 60 rs# [004] 60 ERalpha 60 INCB# [003] 60 Cryptococcus neoformans 60 biochemical marker 60 phosphorylated tau 60 urine cytology 60 Cholangiocarcinoma 60 EUS FNA 60 alefacept 60 kaempferol 60 CYP#D# gene 60 CanAg 60 haematopoietic 60 wildtype 60 metastatic neuroendocrine tumors 60 HER2 positive tumors 60 ELISPOT assay 60 glioblastoma tumors 60 neutrophil counts 60 inducible nitric oxide synthase 60 EGFR 60 UGT#A# 60 ovarian carcinoma 60 M#V mutation 60 TP# mutations 60 SNP rs# [001] 60 5alpha reductase 60 fluoroquinolone resistance 60 anti HBs 60 gemcitabine chemotherapy 60 antibody MAb 60 histone deacetylases 60 somatostatin 60 chemopreventive agent 60 IgA antibodies 60 TTF Therapy 60 imipenem 60 bronchial epithelial cells 60 ALK mutations 60 breast cancer subtypes 60 acute lymphoblastic 60 anthracycline containing 60 tumor xenograft models 60 underwent surgical resection 60 imatinib Gleevec ® 60 leukaemias 60 oral squamous cell 60 papillary 60 nilotinib 60 paclitaxel cisplatin 60 proximal colon 60 lymphopenia 60 Dasatinib 60 platelet reactivity 60 metastatic lung cancer 60 T#I mutation 60 Cervista HPV HR 60 imatinib resistance 60 non mutated KRAS 60 prior chemotherapy regimens 60 bronchoalveolar 60 P selectin 60 NSCLC tumors 60 castration resistant 60 P. gingivalis 60 pituitary adenomas 60 metastatic kidney 60 LRAT 60 lactate dehydrogenase 60 TNFalpha 60 KRAS mutations occur 60 hypoxia inducible factor 60 lymphocytic 60 CDKN2A 60 MAGE A3 ASCI 60 hematologic toxicity 60 renal carcinoma 60 JAK2 enzyme 60 standard chemotherapy regimen 60 CXCL5 60 thyroid carcinomas 60 IGFBP2 60 lung adenocarcinoma 60 malignant ovarian 60 germline mutation 60 rituximab Rituxan 60 Leydig cell 60 gene APOE4 60 BRCA1 mutation carriers 60 APOL1 60 malignant polyps 60 colorectal adenocarcinoma 60 NKT cells 60 ZACTIMA 60 essential thrombocythemia 60 corticosteroid therapy 60 HMGA2 60 heavily pretreated 60 PCA3 gene 60 asymptomatic carotid stenosis 60 transthyretin 60 oral JAK1 60 downregulated 60 NPM1 60 decitabine 60 PITX2 60 Janus kinase 60 anti angiogenic therapy 60 Raf MEK ERK 60 p# biomarker 60 mycosis fungoides 60 CCR5 delta# 60 systemic ALCL 60 Pemetrexed 60 HER2 positive metastatic breast 60 trans retinoic acid ATRA 60 histologies 60 atypical ductal hyperplasia 60 gemcitabine Gemzar 60 isoenzyme 60 predictive biomarker 60 myeloproliferative diseases 60 FasL 60 5q deletion 60 autoantibody 60 stage IIIA 60 HBsAg 60 papillary RCC 60 serum cortisol 60 Epstein Barr virus EBV 60 EGFR gene 60 virulence determinants 60 Leydig cells 60 clinicopathological features 60 antitumor effect 60 myeloproliferative disorders 60 Fas ligand 60 HLA DR 60 survivin 60 cMET 60 colonic polyps 60 Naive Patients 60 bendamustine 60 hepatocellular carcinoma HCC 60 gastrointestinal stromal tumors GIST 60 carcinoid 60 metachronous 60 IGF1R 60 dasatinib Sprycel 60 gastric cancers 60 leiomyomas 60 PI3K Akt 60 cardiac troponin 60 antiproliferative effects 60 BEXXAR Therapeutic Regimen 60 SETDB1 60 curative resection 59 underwent resection 59 Wwox 59 MUC1 59 hormone deprivation 59 HBeAg positive patients 59 UGT#A# * 59 follicular lymphomas 59 genotypic resistance 59 Cytogenetic 59 axillary nodes 59 CANCIDAS 59 oncoproteins 59 Epratuzumab 59 c myc 59 antiangiogenic agents 59 variant allele 59 T#M 59 biochemical relapse 59 TrkA 59 EBV infection 59 caveolin 1 59 colorectal tumor 59 gastrointestinal stromal tumor GIST 59 Tarceva TM 59 5q 59 ductal cancer 59 MCF7 cells 59 hormone LHRH 59 superficial bladder cancer 59 hepatic enzyme 59 Lyn kinase 59 metastatic lymph nodes 59 latent celiac disease 59 TET2 59 gene rearrangements 59 Helicobacter pylori infection 59 papillary thyroid carcinoma 59 chronic HBV 59 transgenic mouse model 59 PDGFRA 59 micrometastasis 59 melanoma lesions 59 EGFR expression 59 serum HBV DNA 59 pT2 59 SNP rs# [002] 59 refractory chronic lymphocytic 59 K RAS 59 prostate ovarian 59 endometrial cancers 59 estrogen receptor negative 59 p# deficient 59 S. aureus isolates 59 GPC5 59 cell acute lymphoblastic 59 CPE delta N 59 SUVmax 59 diagnostic biomarker 59 splice variants 59 malignant pleural mesothelioma 59 BRCA1 BRCA2 59 nutlin 3a 59 tumor histology 59 Anthracycline 59 azacytidine 59 bortezomib Velcade 59 prognostic indicator 59 corticosteroid dexamethasone 59 #q#.# [001] 59 Colon polyps 59 hydroxyvitamin D levels 59 resistant isolates 59 nodal metastases 59 standard chemotherapy regimens 59 ERK pathway 59 ductal carcinomas 59 PROSTVAC VF 59 IGF 1R 59 PSADT 59 #HT#A 59 IGFBP 59 immunostaining 59 TAp# 59 tipranavir ritonavir 59 IL 1ß 59 antiangiogenic therapy 59 Epstein Barr Virus EBV 59 oxysterols 59 EphB4 59 MLL AF9 59 K ras gene 59 axillary lymph nodes 59 anaplastic astrocytomas 59 dexrazoxane 59 paragangliomas 59 RIP1 59 ZNF# 59 poorer prognosis 59 candidemia 59 #F FDG PET 59 tryptase 59 IgA deficiency 59 molecular abnormalities 59 HBV vaccine 59 N Myc 59 cediranib 59 serotonin receptor 59 FLT3 ITD 59 paclitaxel Taxol 59 interferon pathway 59 cTnT 59 chlamydial 59 operable breast cancer 59 melanocytic nevi 59 c MET 59 CD# CD# 59 melanocyte 59 AML MDS 59 complement inhibitor eculizumab 59 sulfasalazine 59 tumor biopsies 59 fluvastatin 59 grade glioma 59 TNF antagonist 59 ALT normalization 59 TGF alpha 59 tumor suppressor protein 59 amyloid deposition 59 sentinel nodes 59 SSc 59 monoinfected patients 59 xenograft models 59 chloride secretion 59 selectively inhibited 59 independent prognostic marker 59 murine models 59 endometrial ovarian 59 Protein Kinase C 59 refractory chronic myeloid 59 KRAS mutant 59 GSTM1 gene 59 MTT assay 59 Xanafide 59 premalignant 59 cancer mCRC 59 C. pneumoniae 59 recurrent metastatic 59 HLA DQ2 59 NF1 59 hepatic metastases 59 colorectal liver metastases 59 pT3 59 TGF β 59 cytogenetic responses 59 polyp recurrence 59 galiximab 59 alanine aminotransferase 59 oesophageal adenocarcinoma 59 carcinoids 59 lymphomas 59 SCIg 59 melatonin receptor 59 tumor necrosis 59 bFGF 59 bladder carcinoma 59 β amyloid 59 Her2 59 IL #R 59 Macrophage 59 vinca alkaloid 59 ependymomas 59 MMP9 59 V#E 59 malignant prostate 59 HPV# 59 HERCEPTIN 59 colon carcinoma 59 cytolytic 59 HER2 positive cancers 59 lymphomas leukemias 59 mitogen activated protein kinase 59 herpesviruses 59 nasopharyngeal carcinoma 59 BMP2 59 commonly mutated genes 59 activating mutation 59 tumor antigen 59 eribulin mesylate 59 Amphinex ® 59 precancerous tissues 59 carcinoid tumors 59 thyrotropin 59 myelodysplastic myeloproliferative diseases 59 NFkB 59 posaconazole 59 genetic variants associated 59 distant metastases 59 pharmacokinetic interactions 59 BRAF protein 59 Chronic Lymphocytic Leukemia CLL 59 DEAR1 59 mapatumumab 59 nonproliferative 59 aspartate aminotransferase 59 SGPT 59 elevated ALT 59 chemotherapeutic drug 59 lymphoid cells 59 variant alleles 59 claudin 59 mutated KRAS gene 59 immunofluorescence staining 59 bexarotene 59 immunochemical 59 Gastrointestinal Stromal Tumors 59 ritonavir boosted 59 azacitidine 59 inhibitory receptor 59 DNMT1 59 lymphoid 59 pancreatic carcinoma 59 rituximab monotherapy 59 AEG# 59 renal toxicity 59 IDH1 mutation 59 fallopian tube cancers 59 FUS1 59 Gorlin syndrome 59 severe hypersensitivity reactions 59 TMPRSS2 ERG fusion 59 prognostic biomarker 59 sunitinib Sutent 59 squamous cell carcinoma SCC 59 EGFR HER2 59 NovoTTF 59 situ CIS 59 Histologic 59 miRNA expression 59 Paraplatin ® 59 CHOP chemotherapy 59 chlamydial infection 59 resectable 59 CCN2 59 beta1 integrin 59 pheochromocytoma 59 GRASPA ® 59 APOE4 59 GRP# 59 histologic subtypes 59 subclinical hyperthyroidism 59 mammary cancers 59 neuroendocrine carcinoma 59 epithelial tissues 59 S aureus 59 CYP#C# [001] 59 endoplasmic reticulum stress 59 Akt activation 59 anaplastic lymphoma kinase 59 interferon gamma 59 PHD2 59 fluoropyrimidine 59 prolonged QT interval 59 adjuvant cisplatin 59 airway hyperresponsiveness 59 RASSF1A 59 metastatic tumors 59 poly ADP ribose polymerase 59 hepatocellular cancer 59 AMACR 59 Ribavirin causes 59 EoE 59 Ceflatonin 59 cell malignancies 59 vitro assay 59 p tau 59 DRB1 * 59 lymph node involvement 59 neutralizing antibody 59 mycophenolate mofetil 59 chlorambucil 59 mitochondrial toxicity 59 tumor subtypes 58 clonogenic 58 indolent NHL 58 stage IIIb IV 58 refractory metastatic 58 proteasome inhibitor 58 NGAL 58 protein tyrosine phosphatase 1B 58 nucleoside analogue 58 complete cytogenetic 58 chemokine receptor 58 BRCA2 carriers 58 LHRH receptors 58 skeletal metastases 58 TMEM#B 58 obstructive coronary artery 58 neovasculature 58 L. pneumophila 58 low expressors 58 BRCA1 mutation 58 immunohistochemical staining 58 uPAR 58 endocrine tumors 58 resected pancreatic cancer 58 prognostic markers 58 mutant allele 58 TCF#L# 58 seminomas 58 mutant BRAF 58 ß catenin 58 osteosarcomas 58 indinavir 58 promoter methylation 58 TEAEs 58 bcl 2 58 synovial tissue 58 Candida infection 58 protein tyrosine phosphatase 58 TRAIL R1 58 fulvestrant 58 TNF Tumor Necrosis Factor 58 E#F# 58 constitutively expressed 58 lung metastases 58 prognostic marker 58 preoperative chemotherapy 58 TRAIL induced apoptosis 58 papillomas 58 estrogen receptor ER 58 ixabepilone 58 glutamic acid decarboxylase 58 invasive candidiasis 58 busulfan 58 Crizotinib 58 promoter hypermethylation 58 mTOR mammalian target 58 gastric carcinomas 58 radiosensitive 58 trabectedin 58 EphB2 58 fluorouracil leucovorin 58 adjuvant radiotherapy 58 temozolomide Temodar 58 Hormone Refractory Prostate Cancer 58 BMS # 58 esophageal squamous cell carcinoma 58 liposomal amphotericin B 58 replicon 58 chromosomal mutations 58 hormone receptor status 58 pulmonary infiltrates 58 non squamous NSCLC 58 docetaxel chemotherapy 58 PTEN gene 58 Treg cell 58 Letairis ambrisentan 58 bullous 58 anti JCV antibodies 58 serum homocysteine 58 NPM1 mutations 58 C. albicans 58 castrate resistant 58 ADAM# 58 VZV 58 lymphoid tumors 58 ductal breast cancer 58 SOD1 gene 58 Cathepsin B 58 Factor Receptor 58 antithymocyte globulin 58 noncarriers 58 Alkaline Phosphatase 58 renal tumors 58 Akt